Cardarine – what is it and what does it do?

Pharmacological class: a PPARδ agonist, not a SARM

Cardarine, also known as GW-501516 or Endurobol, is often grouped with SARMs. Mechanistically, this is incorrect. Although catalogues commonly place it alongside groups such as SARMs in capsules, it does not act on androgen receptors. GW-501516 is an agonist of the PPARδ receptor, a transcription factor described as a regulator of lipid metabolism and inflammatory signalling in many cell types (Bojic & Huff, 2013).

In preclinical models, PPARδ activation was associated with a shift in energy metabolism towards fatty acid oxidation. The compound has been investigated in three groups of models: aerobic capacity in mice, lipid metabolism in cellular and animal models, and, in short clinical studies, lipoprotein metabolism in people with dyslipidaemia.

How does GW-501516 work?

PPARδ receptor activation initiates a cascade of metabolic changes that may translate into more economical energy use during exercise. Three areas are most commonly discussed: endurance, fatty acid oxidation observed in models, and effects on metabolic parameters.

Aerobic capacity in animal models

This area has mainly been described in mouse models. In a study of Kunming mice, GW-501516 prolonged running to exhaustion and increased the proportion of oxidative muscle fibres, both in animals undergoing regular exercise and in animals without such conditioning. Metabolomic analysis indicated increased fatty acid utilisation with reduced glucose use; the authors emphasised that this mechanism differs from that triggered by exercise alone (Chen et al., 2015). These findings concern a mouse model and have not been confirmed in human clinical trials.

GW-501516 and fatty acid metabolism

The second area is lipid metabolism, investigated both in an animal model and in a short human clinical study:

• Fatty acid oxidation (mouse model): GW-501516 increased levels of intermediate metabolites and enzymes in the fatty acid oxidation pathway while reducing glucose utilisation (Chen et al., 2015).
• Lipoprotein metabolism (human study): in a randomised, double-blind crossover study involving 13 men with dyslipidaemia and central obesity, GW-501516 reduced plasma triglyceride, fatty acid and apolipoprotein B concentrations and accelerated hepatic clearance of VLDL particles over six-week periods (Ooi et al., 2011). This was a short-term study with metabolic endpoints.

Reagents used in lipid metabolism research also include compounds with entirely different mechanisms, such as Yohimbine 5 mg, an α2-adrenergic receptor antagonist. These are separate research tools with different activity profiles and should not be treated as equivalent.

Cardarine (GW-501516): effects reported in research

Any discussion of Cardarine’s “effects” requires a clear distinction between findings from animal models and early clinical studies and claims made in marketing. The following overview describes only observations from published literature, within a research framework and without suggesting use in humans.

Aerobic capacity (animal models). The most frequently cited effect comes from the mouse-model study by Narkar et al. (2008): mice receiving GW-501516 showed increased running endurance and, in combination with exercise, reprogramming of muscle fibres from type II (fast-twitch) towards type I (slow-twitch, oxidative). This effect was observed in animals; it has not been confirmed in long-term human clinical trials.

Lipid profile (early clinical studies). Early phase I/II clinical studies conducted by GSK in people with dyslipidaemia reported increases in HDL cholesterol of roughly ten to twenty per cent, decreases in triglycerides and LDL, and reductions in inflammatory markers. These were short-term studies; the programme was discontinued in 2007 before further evaluation.

Energy metabolism (animal and cellular models). Preclinical models showed increased fatty acid beta-oxidation, mitochondrial biogenesis and a shift in muscle fuel preference towards lipid oxidation, as described in the previous section.

None of these effects supports a recommendation for use in humans. GW-501516 is not a medicine, and its clinical development was halted because of the oncological signal described later in this article. Effects observed in research are not the same as a safe, confirmed outcome in humans.

GW-501516 research status and the question of human use

GW-501516 functions as a Research Use Only reagent and has no approved recommendations for use in humans. The clinical programme was halted at an early stage, so no recommendations for use have been approved or validated in humans. In preclinical literature, the compound was administered to animal models under strictly controlled laboratory conditions, and the observed relationships, including the toxicological signal, were dose- and exposure-dependent. These data cannot be translated directly into human use.

For a reagent purchaser, this means there are no recommendations on serving size, frequency or timing of administration. GW-501516 is not intended for consumption or use in humans; scientific analysis considers it solely in the context of laboratory research on the PPARδ receptor.

Cardarine (GW-501516): side effects and safety in research

For readers seeking a consolidated overview of GW-501516 side effects, this section brings together what is known about the molecule’s safety profile from published scientific literature. The picture is mixed: short-term human data suggest relatively good tolerability, but long-term toxicological studies in rodents revealed a signal that led GSK to halt the clinical programme. The signal is serious enough that omitting it would make any account of GW-501516 misleading.

Short-term effects observed in humans

In short-term phase I/II clinical studies (from 2 to 12 weeks), GW-501516 in patients with dyslipidaemia showed a tolerability profile described as relatively good. Reported side effects were mainly mild and included:

• Mild gastrointestinal complaints (nausea, discomfort)
• Headaches in isolated cases
• No significant changes in liver parameters within the short observation period

Short-term clinical studies did not reveal oncological signals, but this does not establish their absence. The observation period, with the longest published phase II clinical trials lasting 12 weeks, is too short to detect cancers developing over years.

The oncological signal from preclinical studies: why GSK halted the programme

In two-year toxicological studies in rodents, a standard FDA requirement for compounds intended for long-term therapy, GW-501516 induced tumours in several organs in a dose- and exposure-dependent manner. This signal was serious enough to lead GSK to halt the clinical programme in 2007.

No long-term human data

The most serious gap in the GW-501516 safety profile is the absence of long-term clinical trials in humans. Short-term trials did not reveal oncological signals, but they were designed around metabolic endpoints (HDL, LDL, triglycerides), not oncological ones. There are no published data from clinical trials lasting longer than a few months.

In practice, the long-term safety of GW-501516 in humans remains undetermined. We do not know whether the oncological signal in the rat model translates meaningfully to humans; nor do we know that it does not. Absence of data remains absence of data. In clinical pharmacology, it calls for caution, not optimism.

WADA status: a health warning, not just a sporting integrity issue

In 2009 the World Anti-Doping Agency (WADA) added GW-501516 to its Prohibited List — initially under gene doping (M3). In 2012 it was moved to section S4, hormone and metabolic modulators; on the 2026 List it appears under S4.4 — Metabolic modulators.

In 2013, WADA issued an unprecedented public warning to athletes, communicating not only the sporting ban but also the health risk associated with GW-501516. This is a rare case of an anti-doping agency actively warning against a substance for medical, rather than solely regulatory, reasons [source: WADA Open Letter 2013, publicly available WADA document].

Regulatory status: RUO, no registration as a medicine

GW-501516 has not been registered as a medicine in any major jurisdiction. After GSK halted its programme in 2007, no other pharmaceutical company took up clinical development. In international trade, GW-501516 functions as a research reagent (Research Use Only): a chemical substance for laboratory research, not intended for human use and with no approved recommendations for use.

RUO reagents in this group are listed in the Cardarine (GW-501516) category.

What we do not know: an honest account of the evidence gaps

• Whether the carcinogenic signal in rats translates to humans, on what scale and in which organs
• The safety profile after years of daily exposure in humans (no studies)
• What human dose corresponds to the toxic dose in rats (interspecies extrapolation is complex)
• Whether special populations, including pregnant or breastfeeding people and patients with a history of oncological risk, show particular susceptibility

The oncological signal for GW-501516 in the rat model is a substantial regulatory and toxicological warning. Human data are insufficient for a full risk assessment. GW-501516 remains a small-molecule research compound, a PPARδ agonist (Research Use Only), without registration as a medicine. Its use falls outside the regulatory framework of an RUO reagent and is neither endorsed nor recommended by One Peptides. The signal that led GSK to halt clinical trials remains relevant: no newer data have superseded it.